FatiAbGen International is the Swiss subsidiary of FatiAbGen Co. Ltd., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.
NewBiologix is a company developing a proprietary and breakthrough platform for the advanced engineering of cell lines. The company is committed to improving the production of viral vectors used in gene therapy by combining an innovative bioinformatics platform with advanced R&D experimentation.